Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The newly certified kits are designed for early detection and large-scale screening programs
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Company to launch product after the expiry of semaglutide patent in India
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
Subscribe To Our Newsletter & Stay Updated